MedMen Enterprises Inc. has admitted defeat, citing monetary woes and an lack of ability to settle its money owed, revealed Amit Pandey, the previous chief monetary officer of the hashish firm, late Friday.
MedMen, as soon as a celebrated pioneer within the hashish trade and dubbed the ‘Apple retailer of weed,’ has been hit by a string of setbacks in recent times. These embody monetary woes, the shuttering of stores, workforce reductions, authorized battles, and inner disputes amongst high executives, all of which have led to the corporate’s present predicament.
In a press launch issued on Friday, MedMen declared that they’ve fastidiously assessed the corporate’s and its subsidiaries’ present monetary state. This evaluation additionally consists of their incapacity to satisfy monetary obligations as they arrive and the upcoming actions by secured collectors. To that finish, they’ve reached the difficult determination to stop operations and provoke Chapter Proceedings and Receivership Proceedings.”
Contemplating these components and with no viable options at hand, the Firm’s board of administrators concluded that continuing with the Chapter Proceedings and Receivership Proceedings was within the Firm’s greatest curiosity,” the assertion continued.
Right here Are A Few Indications
As soon as revered as a titan within the hashish trade, with a valuation hovering as excessive as $1.7 billion as a public entity, MedMen confronted imminent monetary collapse over a yr in the past, as revealed in a December 2022 regulatory submitting with the Securities and Alternate Fee. At the moment, the corporate possessed a mere $15.6 million in money whereas grappling with a staggering $137.4 million debt load.
Following its preliminary monetary struggles, MedMen confronted a collection of challenges. Retailer closures and stock liquidation started in California, and the corporate defaulted on funds, resulting in severed partnerships with main manufacturers. Landlords demanded overdue hire funds. Amid this turmoil, high executives and board members began to depart, signaling deeper turmoil throughout the firm, because the Inexperienced Market Report reported.
What Triggered the Downfall?
The crux of the difficulty possible stems from the corporate’s swift growth, pushed by the preliminary pleasure surrounding the 2018 legalization of hashish in California. Nonetheless, as is usually the case nationwide, legalization marked only the start, resulting in confrontations with the intricate realities of an trade rife with regulatory limitations, hefty taxes, and hampered by federal legislation.
Regardless of having fun with early triumphs, MedMen encountered a slew of obstacles, together with authorized disputes, unsuccessful acquisitions, and competitors from each authorized and underground hashish markets.
Six years following an IPO that propelled its valuation to over $3 billion, MedMen, a hashish retailer, now holds negligible worth. Its current chapter submitting in a California court docket signifies the ultimate blow in a dramatic downfall for a corporation emblematic of the broader trials going through the authorized hashish sector.
“MedMen has been ‘DeadMen’ for a lot of buyers for fairly a while,” remarked hashish trade analyst Alan Brochstein to Fortune. “Whereas this end result could have been foreseeable to some, not everybody anticipated it.”
MedMen swiftly penetrated the authorized hashish scene following California’s legalization of leisure use in 2016. Initially lauded because the “Apple retailer of weed,” MedMen’s stores boasted “smooth branding” and a “premium design aesthetic,” as outlined in a 2022 investor presentation.
To capitalize on the anticipated surge in authorized hashish demand, MedMen launched into an bold growth, opening upscale storefronts in outstanding areas reminiscent of Venice Seaside, New York’s Fifth Avenue, and close to the Las Vegas Strip. Using a wave of optimistic media protection and public pleasure surrounding authorized hashish, the corporate loved important consideration.
Beneath the management of co-founder Adam Bierman, who launched the enterprise in his twenties, MedMen made its debut on the general public market in 2018 at barely above $3 per share. Investor enthusiasm drove its share worth to double by the yr’s finish.
Buoyed by early triumphs, MedMen aimed for fast development, accumulating a whole bunch of thousands and thousands in debt and pursuing an intensive $682 million merger with competitor PharmaCann. Nonetheless, the merger collapsed following a Division of Justice announcement of an antitrust investigation, exacerbating MedMen’s monetary woes.
Because the broader hashish market confronted headwinds, compounded by issues over regulatory scrutiny of hazardous vape cartridges, investor confidence waned, hindering MedMen’s potential to repay collectors. They went public in 2018. And by the point we reached 2020, [MedMen] was in massive hassle, remarked Brochstein. They took on an excessive amount of debt and made overzealous guarantees.”
All through 2019, MedMen’s inventory plummeted, shedding 92% of its worth as the corporate grappled with exorbitant tax obligations and struggled to compete in opposition to unlicensed sellers providing decrease costs. The onset of the pandemic, nonetheless, triggered a surge in demand, offering MedMen and different hashish retailers with a reprieve by way of 2020.
The hashish trade did higher than anyone would have anticipated in 2020. Regardless of this sudden boon, it proved inadequate. At its peak, MedMen boasted 25 branches nationwide and had bold plans for worldwide growth. Nonetheless, as we speak, all however two places have completely shuttered.
Bierman, the co-founder, was ousted in early 2020 amidst a slew of high-profile lawsuits alleging racism, inventory manipulation, and misuse of firm funds to finance an extravagant life-style full with non-public safety and customised Cadillac Escalades.
A Fall From Grace
MedMen’s chapter submitting, unveiling over $400 million in liabilities, marks the ultimate chapter in its beautiful collapse. Hindered by steep rates of interest and bitter investor sentiment, the corporate couldn’t refinance its debt, finally ceasing SEC disclosures altogether.
“The capital markets have been lower off for them in order that they could not repair their outdated errors,” famous Brochstein.
The once-vibrant unicorn of the hashish trade now stands bankrupt, with belongings valued at a mere $1 (sure, only a greenback) and liabilities totaling $410 million, as detailed within the firm’s chapter paperwork. Predictably, MedMen’s shares, dormant for weeks, face imminent delisting following its steep downward spiral in 2024. Initially of this decline, the OTC Market devalued the corporate to zero in January.
MedMen’s full downfall serves as a sobering lesson within the ever-evolving hashish sector, the place as soon as a fault seems, the complete construction can unravel swiftly.
MEDMEN BANKRUPTCY EXPLAINED, READ ON…
FRANK SEGALL TALKS MEDMEN DISTRESSED DEBT!
